Human papillomavirus 16-positive (HPV16+) cancers - Pipeline Insight, 2022

Human papillomavirus 16-positive (HPV16+) cancers - Pipeline Insight, 2022

DelveInsight’s, “Human papillomavirus 16-positive (HPV16+) cancers - Pipeline Insight, 2022,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Human papillomavirus 16-positive (HPV16+) cancers pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Human papillomavirus 16-positive (HPV16+) cancers Understanding

Human papillomavirus 16-positive (HPV16+) cancers: Overview

Human papillomavirus 16-positive (HPV16+) cancer is a type of cancer that is caused due to the infection of HPV virus. The infection can lead to 70% of cervical cancers and to some extent squamous cell head and neck cancer. This cancer is more prevalent among women than men and can be sexually transmitted. Individual with weakened immune system, co-infection with other STDs agents are more likely to progress to pre cancer, and cancer associated to HPV virus infection.

""Human papillomavirus 16-positive (HPV16+) cancers - Pipeline Insight, 2022"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Human papillomavirus 16-positive (HPV16+) cancers pipeline landscape is provided which includes the disease overview and Human papillomavirus 16-positive (HPV16+) cancers treatment guidelines. The assessment part of the report embraces, in depth Human papillomavirus 16-positive (HPV16+) cancers commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Human papillomavirus 16-positive (HPV16+) cancers collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

● The companies and academics are working to assess challenges and seek opportunities that could influence Human papillomavirus 16-positive (HPV16+) cancers R&D. The therapies under development are focused on novel approaches to treat/improve Human papillomavirus 16-positive (HPV16+) cancers.

Human papillomavirus 16-positive (HPV16+) cancers Emerging Drugs Chapters

This segment of the Human papillomavirus 16-positive (HPV16+) cancers report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Human papillomavirus 16-positive (HPV16+) cancers Emerging Drugs

● VB 10.16: Vaccibody AS

Vaccibody AS’ lead drug candidate, VB 10.16 is a therapeutic DNA vaccine in the development for the treatment of HPV16+ induced pre- malignancies and malignancies. The drug has demonstrated favorable outcome in its phase I trial. It induces immunologic cytotoxicity to curb the cancer progression.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Non-resectable HPV 16-Positive Cervical Cancer.

● GX 188E: Genexine

Genexine “breakthrough” drug GX 188E is a DNA therapeutic vaccine which is currently being evaluated for the treatment of HPV 16+ associated cancer. The drug target and activate dendritic cells and induce tumor-specific CD8+ immune response.Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of HPV Type 16 and/or 18 Positive Patients With Cervical Intraepithelial Neoplasia 3 (CIN 3).

Further product details are provided in the report……..

Human papillomavirus 16-positive (HPV16+) cancers: Therapeutic Assessment

This segment of the report provides insights about the different Human papillomavirus 16-positive (HPV16+) cancers drugs segregated based on following parameters that define the scope of the report, such as:

● Major Players in Human papillomavirus 16-positive (HPV16+) cancers

There are approx. 10+ key companies which are developing the therapies for Human papillomavirus 16-positive (HPV16+) cancers. The companies which have their Human papillomavirus 16-positive (HPV16+) cancers drug candidates in the most advanced stage, i.e. phase II include, Vaccibody AS.

● Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

● Route of Administration

Human papillomavirus 16-positive (HPV16+) cancers pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Intravenous

Subcutaneous

Intramuscular

Topical.

● Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Vaccines

Small molecule

● Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Human papillomavirus 16-positive (HPV16+) cancers: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Human papillomavirus 16-positive (HPV16+) cancers therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Human papillomavirus 16-positive (HPV16+) cancers drugs.

Human papillomavirus 16-positive (HPV16+) cancers Report Insights

Human papillomavirus 16-positive (HPV16+) cancers Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Human papillomavirus 16-positive (HPV16+) cancers Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Human papillomavirus 16-positive (HPV16+) cancers drugs?

How many Human papillomavirus 16-positive (HPV16+) cancers drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Human papillomavirus 16-positive (HPV16+) cancers?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Human papillomavirus 16-positive (HPV16+) cancers therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Human papillomavirus 16-positive (HPV16+) cancers and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

● Vaccibody As

● Genexine

● Transgene

● Inovio Pharmaceuticals

Key Products

VB10.16

GX 188E

TG4001

MEDI0457